Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NexImmune, Inc.NEXI · Entity 89921 | Director | July 05, 2023 | July 07, 2023 |
| PROKIDNEY CORP.PROK · Entity 5181 | Director · Chief Executive Officer | January 16, 2023 | January 18, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NexImmune, Inc.
Report date July 05, 2023 · Filed July 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.29 · Expires 2033-07-04 | Direct | 44,983 |
Reported balance
After 2023-07-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-05 · Grant · Acquired 44,983 · Balance 44,983 |
PROKIDNEY CORP.
Report date January 16, 2023 · Filed January 18, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43 · Expires 2033-01-16 | Direct | 1,011,500 |
Reported balance
After 2023-01-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-16 · Grant · Acquired 1,011,500 · Balance 1,011,500 F1: The option vests in substantially equal monthly installments over the four year period beginning on January 16, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in substantially equal monthly installments over the four year period beginning on January 16, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 05, 2023 Filed Jul 7, 2023 16:16 UTC | NexImmune, Inc. NEXI · Entity 89921 | GrantStock Option (right to buy) · Derivative | 44,983 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0000950170-23-032243 · ownership.xml · derivative · entry 1 Bertram Timothy · CIK 0001488033 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,983 Underlying: Common Stock · 44,983 shares Expires 2033-07-04 Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:35 UTC | NexImmune, Inc. NEXI · Entity 89921 | GrantStock Option (right to buy) · Derivative | 12,634 | Not disclosed Strike: $1.64 | Not disclosed |
DisclosureSEC source: 0001209191-23-023682 · doc4.xml · derivative · entry 8 Bertram Timothy · CIK 0001488033 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,634 Underlying: Common Stock · 12,634 shares Expires 2037-03-02 F4 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 3, 2017, of which all of the shares subject to such option have vested. F4 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 3, 2017, of which all of the shares subject to such option have vested. F4 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 3, 2017, of which all of the shares subject to such option have vested. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:35 UTC | NexImmune, Inc. NEXI · Entity 89921 | Disposition to issuerStock Option (right to buy) · Derivative | 12,634 | Not disclosed Strike: $2.42 | Not disclosed |
DisclosureSEC source: 0001209191-23-023682 · doc4.xml · derivative · entry 7 Bertram Timothy · CIK 0001488033 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,634 Underlying: Common Stock · 12,634 shares Expires 2037-03-02 F4 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 3, 2017, of which all of the shares subject to such option have vested. F4 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 3, 2017, of which all of the shares subject to such option have vested. F4 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 3, 2017, of which all of the shares subject to such option have vested. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:35 UTC | NexImmune, Inc. NEXI · Entity 89921 | GrantStock Option (right to buy) · Derivative | 23,122 | Not disclosed Strike: $1.64 | Not disclosed |
DisclosureSEC source: 0001209191-23-023682 · doc4.xml · derivative · entry 6 Bertram Timothy · CIK 0001488033 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,122 Underlying: Common Stock · 23,122 shares Expires 2029-03-18 F3 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 19, 2019, of which all of the shares subject to such option have vested. F3 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 19, 2019, of which all of the shares subject to such option have vested. F3 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 19, 2019, of which all of the shares subject to such option have vested. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:35 UTC | NexImmune, Inc. NEXI · Entity 89921 | Disposition to issuerStock Option (right to buy) · Derivative | 23,122 | Not disclosed Strike: $4.31 | Not disclosed |
DisclosureSEC source: 0001209191-23-023682 · doc4.xml · derivative · entry 5 Bertram Timothy · CIK 0001488033 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,122 shares Expires 2029-03-18 F3 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 19, 2019, of which all of the shares subject to such option have vested. F3 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 19, 2019, of which all of the shares subject to such option have vested. F3 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 19, 2019, of which all of the shares subject to such option have vested. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:35 UTC | NexImmune, Inc. NEXI · Entity 89921 | GrantStock Option (right to buy) · Derivative | 9,556 | Not disclosed Strike: $1.64 | Not disclosed |
DisclosureSEC source: 0001209191-23-023682 · doc4.xml · derivative · entry 4 Bertram Timothy · CIK 0001488033 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,556 Underlying: Common Stock · 9,556 shares Expires 2031-02-10 F2 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested. F2 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested. F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:35 UTC | NexImmune, Inc. NEXI · Entity 89921 | Disposition to issuerStock Option (right to buy) · Derivative | 9,556 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-023682 · doc4.xml · derivative · entry 3 Bertram Timothy · CIK 0001488033 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,556 shares Expires 2031-02-10 F2 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested. F2 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested. F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:35 UTC | NexImmune, Inc. NEXI · Entity 89921 | GrantStock Option (right to buy) · Derivative | 61,678 | Not disclosed Strike: $1.64 | Not disclosed |
DisclosureSEC source: 0001209191-23-023682 · doc4.xml · derivative · entry 2 Bertram Timothy · CIK 0001488033 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,678 Underlying: Common Stock · 61,678 shares Expires 2032-06-12 F1 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Bertram's continued service on such vesting date. F1 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Bertram's continued service on such vesting date. F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Bertram's continued service on such vesting date. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:35 UTC | NexImmune, Inc. NEXI · Entity 89921 | Disposition to issuerStock Option (right to buy) · Derivative | 61,678 | Not disclosed Strike: $1.82 | Not disclosed |
DisclosureSEC source: 0001209191-23-023682 · doc4.xml · derivative · entry 1 Bertram Timothy · CIK 0001488033 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,678 shares Expires 2032-06-12 F1 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Bertram's continued service on such vesting date. F1 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Bertram's continued service on such vesting date. F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Bertram's continued service on such vesting date. Read SEC document |
| January 16, 2023 Filed Jan 18, 2023 21:08 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantEmployee stock option (right to buy) · Derivative | 1,011,500 | $0.00 Strike: $8.43 | $0.00 |
DisclosureSEC source: 0001209191-23-003705 · doc4.xml · derivative · entry 1 Bertram Timothy · CIK 0001488033 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,011,500 Underlying: Class A Ordinary Shares · 1,011,500 shares Expires 2033-01-16 F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on January 16, 2023. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 21:47 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantEmployee stock option (right to buy) · Derivative | 3,639,607 | $0.00 Strike: $10.33 | $0.00 |
DisclosureSEC source: 0001209191-22-054426 · doc4.xml · derivative · entry 1 Bertram Timothy · CIK 0001488033 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,639,607 Underlying: Class A Ordinary Shares · 3,639,607 shares Expires 2032-10-20 F1 · derivative.exercise_date: Awards vest and become exercisable based on the satisfaction of both time and performance vesting conditions. The performance vesting conditions become satisfied in equal one-third tranches upon the Company's Class A ordinary shares exceeding a volume weighted average price hurdle of $15.00, $20.00 and $25.00, respectively, for 20 trading days within any 30 consecutive trading day period occurring prior to July 11, 2027. Once the performance vesting condition for a tranche is satisfied, such tranche will continue to be subject to time-vesting conditions and will vest ratably on each of the first, second and third anniversaries of the date that such tranche satisfied the performance vesting condition described above. Read SEC document |
| July 11, 2022 Filed Jul 14, 2022 01:33 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantCommon Units in ProKidney LP · Derivative | 4,944,938 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-012377 · dp177031_4-bertram.xml · derivative · entry 2 Bertram Timothy · CIK 0001488033 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,944,938 Underlying: Class A Ordinary Shares · 4,944,938 shares Expires not disclosed F3 · security: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis. F3 · derivative.exercise_price: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis. F4 · derivative.exercise_price: These 2,696,469 Common Units and 2,248,469 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire. F4 · derivative.exercise_date: These 2,696,469 Common Units and 2,248,469 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire. F4 · derivative.expiration_date: These 2,696,469 Common Units and 2,248,469 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire. Read SEC document |
| July 11, 2022 Filed Jul 14, 2022 01:33 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantClass B Ordinary Shares · Derivative | 4,944,938 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-012377 · dp177031_4-bertram.xml · derivative · entry 1 Bertram Timothy · CIK 0001488033 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,944,938 Underlying: Class A Ordinary Shares · 4,944,938 shares Expires not disclosed F1 · derivative.exercise_price: Each Class B Ordinary Share has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP ("ProKidney") (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis. F2 · derivative.exercise_price: These 2,696,469 Class B Ordinary Shares and 2,248,469 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire. F2 · derivative.exercise_date: These 2,696,469 Class B Ordinary Shares and 2,248,469 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire. F2 · derivative.expiration_date: These 2,696,469 Class B Ordinary Shares and 2,248,469 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 17:01 UTC | NexImmune, Inc. NEXI · Entity 89921 | GrantStock Option (Right to Buy) · Derivative | 61,678 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001209191-22-037030 · doc4.xml · derivative · entry 1 Bertram Timothy · CIK 0001488033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,678 Underlying: Common Stock · 61,678 shares Expires 2032-06-12 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:22 UTC | NexImmune, Inc. NEXI · Entity 89921 | ConversionSeries A3 Stock · Derivative | 16,440 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-012356 · doc4.xml · derivative · entry 6 Bertram Timothy · CIK 0001488033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,440 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F2 · derivative.exercise_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:22 UTC | NexImmune, Inc. NEXI · Entity 89921 | ConversionSeries A2 Preferred Stock · Derivative | 10,344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-012356 · doc4.xml · derivative · entry 5 Bertram Timothy · CIK 0001488033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,344 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F2 · derivative.exercise_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:22 UTC | NexImmune, Inc. NEXI · Entity 89921 | ConversionSeries A Preferred Stock · Derivative | 44,965 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-012356 · doc4.xml · derivative · entry 4 Bertram Timothy · CIK 0001488033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,965 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F2 · derivative.exercise_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:22 UTC | NexImmune, Inc. NEXI · Entity 89921 | ConversionCommon Stock | 16,440 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-012356 · doc4.xml · nonDerivative · entry 3 Bertram Timothy · CIK 0001488033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:22 UTC | NexImmune, Inc. NEXI · Entity 89921 | ConversionCommon Stock | 10,344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-012356 · doc4.xml · nonDerivative · entry 2 Bertram Timothy · CIK 0001488033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 16:22 UTC | NexImmune, Inc. NEXI · Entity 89921 | ConversionCommon Stock | 44,965 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-012356 · doc4.xml · nonDerivative · entry 1 Bertram Timothy · CIK 0001488033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 14:29 UTC | NexImmune, Inc. NEXI · Entity 89921 | GrantStock Option (right to buy) · Derivative | 9,556 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010658 · doc4.xml · derivative · entry 1 Bertram Timothy · CIK 0001488033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,312 Underlying: Common Stock · 9,556 shares Expires 2025-02-11 F1 · derivative.exercise_date: These stock options will vest and become exercisable at the first anniversary of the vesting commencement date (2/11/21). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.